Dear friends
Can I please have your assistance on this matter?
Many studies in diabetes care, particularly on insulin-treatment, are
carried out in an open-label fashion.
Can one consider the endpoints in a study of diabetes to be so objective
and sufficiently un-biased that this is appropriate to do?
In critical appraisal we learn (and teach) that the measurement of
endpoints should be either blinded or objective (or both).
What is your opinion on this?
Regards
Ulf Eriksson
Karlskrona
Sweden
|